CS277561B6 - Injectable, sterile, apyrogenic solution of anthracyclin glycoside and process for preparing thereof - Google Patents
Injectable, sterile, apyrogenic solution of anthracyclin glycoside and process for preparing thereof Download PDFInfo
- Publication number
- CS277561B6 CS277561B6 CS864708A CS470886A CS277561B6 CS 277561 B6 CS277561 B6 CS 277561B6 CS 864708 A CS864708 A CS 864708A CS 470886 A CS470886 A CS 470886A CS 277561 B6 CS277561 B6 CS 277561B6
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- doxorubicin
- solution
- water
- dissolved
- concentration
- Prior art date
Links
- 229930182470 glycoside Natural products 0.000 title claims description 32
- 150000002338 glycosides Chemical class 0.000 title claims description 26
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000000243 solution Substances 0.000 claims description 170
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 104
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 93
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 75
- 229960004679 doxorubicin Drugs 0.000 claims description 61
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 33
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- -1 inorganic acid salt Chemical class 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 16
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 14
- 229960000975 daunorubicin Drugs 0.000 claims description 14
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 14
- 229960000908 idarubicin Drugs 0.000 claims description 14
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 11
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 10
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 150000007522 mineralic acids Chemical class 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 239000003125 aqueous solvent Substances 0.000 claims description 7
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 239000008121 dextrose Substances 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229920000151 polyglycol Polymers 0.000 claims description 4
- 239000010695 polyglycol Substances 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- 150000004040 pyrrolidinones Chemical class 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 229960002242 chlorocresol Drugs 0.000 claims description 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 claims 2
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 claims 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 claims 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 2
- 238000001914 filtration Methods 0.000 claims 1
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 106
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 86
- 229910052757 nitrogen Inorganic materials 0.000 description 43
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 41
- 239000008215 water for injection Substances 0.000 description 32
- 230000005587 bubbling Effects 0.000 description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 21
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 19
- 229910052782 aluminium Inorganic materials 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 17
- 239000011521 glass Substances 0.000 description 16
- 229920006362 Teflon® Polymers 0.000 description 15
- 229920001971 elastomer Polymers 0.000 description 15
- 239000004809 Teflon Substances 0.000 description 14
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 13
- 239000008232 de-aerated water Substances 0.000 description 12
- 238000006731 degradation reaction Methods 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000008223 sterile water Substances 0.000 description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000012982 microporous membrane Substances 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7s,9s)-7-[(2r,4s,5r,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 239000011123 type I (borosilicate glass) Substances 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 229920005556 chlorobutyl Polymers 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000003113 alkalizing effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000008431 aliphatic amides Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004189 ion pair high performance liquid chromatography Methods 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical class COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- 125000005274 4-hydroxybenzoic acid group Chemical class 0.000 description 1
- VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical compound CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000248349 Citrus limon Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 201000000170 Thyroid lymphoma Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000012544 Viola sororia Nutrition 0.000 description 1
- 241001106476 Violaceae Species 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 201000011199 bladder lymphoma Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 150000004862 dioxolanes Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910001504 inorganic chloride Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000001037 lung lymphoma Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- DDJZTXMTVGFOMH-UHFFFAOYSA-N n,2-dihydroxy-2-methylbutanamide Chemical compound CCC(C)(O)C(=O)NO DDJZTXMTVGFOMH-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008017 ovarian lymphoma Diseases 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001475 prostate lymphoma Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858519452A GB8519452D0 (en) | 1985-08-02 | 1985-08-02 | Injectable solutions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS470886A3 CS470886A3 (en) | 1992-11-18 |
| CS277561B6 true CS277561B6 (en) | 1993-03-17 |
Family
ID=10583216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS864708A CS277561B6 (en) | 1985-08-02 | 1986-06-25 | Injectable, sterile, apyrogenic solution of anthracyclin glycoside and process for preparing thereof |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US4946831A (de) |
| JP (1) | JPH0655667B2 (de) |
| KR (1) | KR920001773B1 (de) |
| CN (1) | CN1064531C (de) |
| AT (1) | AT397463B (de) |
| BE (1) | BE905202A (de) |
| BG (1) | BG60425B2 (de) |
| CA (1) | CA1291037C (de) |
| CH (2) | CH668911C1 (de) |
| CS (1) | CS277561B6 (de) |
| CY (1) | CY1592A (de) |
| DE (1) | DE3621844C2 (de) |
| DK (1) | DK167557B1 (de) |
| ES (1) | ES8801580A1 (de) |
| FI (1) | FI86800C (de) |
| FR (1) | FR2585569B1 (de) |
| GB (2) | GB8519452D0 (de) |
| GR (1) | GR861556B (de) |
| HK (1) | HK93990A (de) |
| HU (1) | HU196123B (de) |
| IE (1) | IE59297B1 (de) |
| IL (1) | IL79129A (de) |
| IT (1) | IT1204906B (de) |
| NL (2) | NL191507C (de) |
| NO (1) | NO170913C (de) |
| NZ (1) | NZ216604A (de) |
| PH (1) | PH22332A (de) |
| PT (1) | PT82865B (de) |
| RU (2) | RU1837883C (de) |
| SE (1) | SE466383C (de) |
| SG (1) | SG80690G (de) |
| UA (1) | UA29383C2 (de) |
| YU (1) | YU44788B (de) |
| ZA (1) | ZA864792B (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977082A (en) | 1985-08-02 | 1999-11-02 | Pharmacia & Upjohn Company | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5124318A (en) * | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.R.L. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| US5124317A (en) | 1985-08-02 | 1992-06-23 | Farmitalia Carlo Erba S.P.A. | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside |
| EP0659435B1 (de) * | 1986-12-05 | 2003-05-14 | Pharmacia Italia S.p.A. | Doxorubicin enthaltende einspritzbare gebrauchsfertige Lösungen gegen Krebs |
| FI883337L (fi) * | 1987-07-16 | 1989-01-17 | Bristol Myers Co | Icke-vattenloesningar av doxorubicinhydroklorin. |
| FI883338A7 (fi) * | 1987-07-16 | 1989-01-17 | Bristol Myers Squibb Co | Doksorubisiinihydrokloridin vesiliuoksia |
| DE3801178A1 (de) * | 1988-01-18 | 1989-07-27 | Hoechst Ag | Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung |
| DE68905577T2 (de) * | 1988-12-05 | 1993-07-01 | Bristol Myers Squibb Co | Doxorubicin-loesungen. |
| FI895733A7 (fi) * | 1988-12-05 | 1990-06-06 | Bristol Myers Squibb Co | Doksorubisiinin vesiliuoksia |
| GB9200247D0 (en) * | 1992-01-07 | 1992-02-26 | Erba Carlo Spa | Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation |
| DE19544532C2 (de) * | 1995-11-29 | 1997-12-11 | Pharma Dynamics Gmbh | Verfahren zum Herstellen eines Doxorubicin-Lyophilisats |
| ATE195526T1 (de) * | 1996-12-16 | 2000-09-15 | Pharmachemie Bv | Verfahren zur herstellung von epirubicin oder zusatzsalzen davon, von daunorubicin |
| NZ336381A (en) | 1996-12-30 | 2000-11-24 | Battelle Memorial Institute | Formulation and method for treating neoplasms by inhalation |
| US20090253220A1 (en) * | 2003-10-28 | 2009-10-08 | Sukanta Banerjee | Absorbing Biomolecules into Gel-Shell Beads |
| WO2006122309A2 (en) * | 2005-05-11 | 2006-11-16 | Sicor, Inc. | Stable lyophilized anthracycline glycosides |
| EP2771034B1 (de) * | 2011-10-25 | 2018-08-08 | Nektar Therapeutics | Topoisomerase-i und -ii hemmer zur anwendung bei der behandlung von krebspatienten |
| CN102614118B (zh) * | 2012-03-15 | 2014-04-30 | 北京协和药厂 | 注射用盐酸表柔比星制剂的制备方法及制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU33730B (en) * | 1967-04-18 | 1978-02-28 | Farmaceutici Italia | Process for preparing a novel antibiotic substance and salts thereof |
| GB1457632A (en) * | 1974-03-22 | 1976-12-08 | Farmaceutici Italia | Adriamycins |
| GB1500421A (en) * | 1975-01-22 | 1978-02-08 | Farmaceutici Italia | Optically active anthracyclinones |
| US4039663A (en) * | 1975-03-19 | 1977-08-02 | Societa' Farmaceutici Italia S.P.A. | Daunomycins, process for their uses and intermediates |
| FR2314726A1 (fr) * | 1975-06-16 | 1977-01-14 | Rhone Poulenc Ind | Nouveaux derives du naphtagene, leur preparation et les compositions qui les contiennent |
| GB1511559A (en) * | 1975-09-26 | 1978-05-24 | Farmaceutici Italia | Anthracycline glycosides |
| FR2397425A1 (fr) * | 1977-07-11 | 1979-02-09 | Rhone Poulenc Ind | Nouveaux derives de la daunorubicine, leur preparation et les compositions qui les contiennent |
| DE2738656A1 (de) * | 1977-08-26 | 1979-03-08 | Microbial Chem Res Found | Anthracyclinglycoside, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| GB2007645B (en) * | 1977-10-17 | 1982-05-12 | Stanford Res Inst Int | Benzyl anthracyclines and pharmaceutical compositions containing them |
| US4177264A (en) * | 1977-10-17 | 1979-12-04 | Sri International | N-benzyl anthracyclines |
| FR2430425A1 (fr) * | 1978-07-07 | 1980-02-01 | Rhone Poulenc Ind | Nouveaux derives de la daunorubicine, leur preparation et les compositions pharmaceutiques qui les contiennent |
| FR2433027A1 (fr) * | 1978-08-08 | 1980-03-07 | Rhone Poulenc Ind | Nouveau procede de preparation de derives de la doxorubicine |
| US4325947A (en) * | 1981-05-12 | 1982-04-20 | Farmitalia Carlo Erba S.P.A. | 4-Demethoxy-4'-deoxydoxorubicin |
| US4438105A (en) * | 1982-04-19 | 1984-03-20 | Farmaitalia Carlo Erba S.P.A | 4'-Iododerivatives of anthracycline glycosides |
| US4464529A (en) * | 1982-07-20 | 1984-08-07 | Sri International | Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin |
| JPS6092212A (ja) * | 1983-10-26 | 1985-05-23 | Kyowa Hakko Kogyo Co Ltd | ドキソルビシン塩の製剤 |
| EP0659435B1 (de) * | 1986-12-05 | 2003-05-14 | Pharmacia Italia S.p.A. | Doxorubicin enthaltende einspritzbare gebrauchsfertige Lösungen gegen Krebs |
-
1985
- 1985-08-02 GB GB858519452A patent/GB8519452D0/en active Pending
-
1986
- 1986-06-16 YU YU1035/86A patent/YU44788B/xx unknown
- 1986-06-16 GR GR861556A patent/GR861556B/el unknown
- 1986-06-17 IE IE159886A patent/IE59297B1/en not_active IP Right Cessation
- 1986-06-17 IL IL79129A patent/IL79129A/xx not_active IP Right Cessation
- 1986-06-18 GB GB8614800A patent/GB2178311B/en not_active Expired
- 1986-06-19 ES ES556291A patent/ES8801580A1/es not_active Expired
- 1986-06-19 SE SE8602743A patent/SE466383C/sv not_active IP Right Cessation
- 1986-06-19 FI FI862629A patent/FI86800C/fi not_active IP Right Cessation
- 1986-06-20 FR FR868608964A patent/FR2585569B1/fr not_active Expired - Lifetime
- 1986-06-20 HU HU862614A patent/HU196123B/hu unknown
- 1986-06-20 NZ NZ216604A patent/NZ216604A/xx unknown
- 1986-06-24 CH CH2534/86A patent/CH668911C1/de not_active IP Right Cessation
- 1986-06-24 CH CH02158/99A patent/CH690490C2/de not_active IP Right Cessation
- 1986-06-25 CS CS864708A patent/CS277561B6/cs not_active IP Right Cessation
- 1986-06-26 NO NO19862587A patent/NO170913C/no not_active IP Right Cessation
- 1986-06-26 IT IT20917/86A patent/IT1204906B/it active Protection Beyond IP Right Term
- 1986-06-27 RU SU864027713A patent/RU1837883C/ru active
- 1986-06-27 PT PT82865A patent/PT82865B/pt unknown
- 1986-06-27 NL NL8601698A patent/NL191507C/nl not_active IP Right Cessation
- 1986-06-27 DK DK306286A patent/DK167557B1/da not_active IP Right Cessation
- 1986-06-27 CA CA000512613A patent/CA1291037C/en not_active Expired - Lifetime
- 1986-06-27 JP JP61149878A patent/JPH0655667B2/ja not_active Expired - Lifetime
- 1986-06-27 UA UA5011936A patent/UA29383C2/uk unknown
- 1986-06-27 ZA ZA864792A patent/ZA864792B/xx unknown
- 1986-06-28 CN CN86104283A patent/CN1064531C/zh not_active Expired - Lifetime
- 1986-06-28 KR KR1019860005231A patent/KR920001773B1/ko not_active Expired
- 1986-06-30 PH PH33966A patent/PH22332A/en unknown
- 1986-06-30 DE DE3621844A patent/DE3621844C2/de not_active Revoked
- 1986-06-30 AT AT0176886A patent/AT397463B/de active Protection Beyond IP Right Term
- 1986-07-31 BE BE0/216997A patent/BE905202A/fr not_active IP Right Cessation
-
1989
- 1989-07-27 US US07/385,999 patent/US4946831A/en not_active Expired - Lifetime
-
1990
- 1990-10-04 SG SG806/90A patent/SG80690G/en unknown
- 1990-11-15 HK HK939/90A patent/HK93990A/xx not_active IP Right Cessation
-
1992
- 1992-04-03 CY CY1592A patent/CY1592A/en unknown
- 1992-06-24 RU SU5011936A patent/RU2110263C1/ru active
-
1993
- 1993-12-21 BG BG098321A patent/BG60425B2/bg unknown
-
2000
- 2000-07-18 NL NL300011C patent/NL300011I1/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6632799B2 (en) | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside | |
| CS277561B6 (en) | Injectable, sterile, apyrogenic solution of anthracyclin glycoside and process for preparing thereof | |
| US6107285A (en) | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside | |
| CZ2002291A3 (cs) | Farmaceuticky stabilní přípravek oxaliplatiny k parenterální aplikaci | |
| KR960007861B1 (ko) | 항종양성 안트라사이클린 글리코사이드-함유 즉시-사용형 주사 용액 및 이의 제조방법 | |
| US5124318A (en) | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside | |
| KR100279341B1 (ko) | 항악성종양제 독소루비신의 안정한 주사액 및 그 제조방법 | |
| SI8611035A8 (sl) | Postopek pripravljanja injekcijske raztopine, pripravljene za uporabo, ki vsebuje protitumorni, antraciklinski glikozid | |
| HK1011288B (en) | Injectable ready-to-use solutions containing doxorubicin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF00 | In force as of 2000-06-30 in czech republic | ||
| MK4A | Patent expired |
Effective date: 20060625 |